Stock Movers: CoreWeave, Eli Lilly, Tesla (Podcast)

CoreWeave shares plunged 20% in the first three sessions of the week as its debt traded at distressed levels and swaps priced in a more than 60% chance of default within five years, though some investors and analysts cited strong demand for AI computing. Eli Lilly’s Foundayo received a positive recommendation from an EMA committee for obesity and type 2 diabetes; the European Commission makes the final approval decision. Tesla revealed a Roadster prototype, with production expected in 2028, amid consecutive annual sales declines and criticism of its stagnant lineup.

Analysis

CRWV is the clearest risk signal: widening credit stress can raise funding costs and constrain GPU capacity before customer demand weakens. That creates a feedback loop—less ability to finance or deploy compute can impair utilization and customer delivery, further weakening creditor confidence. But bond-implied default risk is a market price, not a forecast; strong contracted demand or access to refinancing could drive a sharp reversal. Over 1–3 months, watch bond prices, refinancing terms, liquidity disclosures, and customer concentration—not AI demand headlines alone. Over 6–18 months, capacity financing and competition from hyperscalers matter more than the sector growth narrative.

For LLY, the regulatory step reduces one hurdle but does not establish launch economics. The key incremental variables are final authorization, supply readiness, payer access, and whether an oral option expands the treated market or shifts patients from existing products. The latter could limit incremental revenue even if adoption is strong. Tesla’s reveal is a sentiment catalyst, not near-term earnings evidence: a 2028 production horizon leaves room for execution delays, while brand excitement may temporarily support the multiple. No direct read-through to SpaceX economics follows from the collaboration alone.

Key Decisions for Investors

• CRWV: Do not buy the equity solely on the AI-demand narrative. Consider defined-risk downside exposure only if bond weakness persists and liquidity or refinancing disclosures deteriorate; avoid chasing a short if credit stabilizes. Falsifiers: improving bond prices, credible funding access, and evidence that contracted capacity is being deployed on schedule.
• LLY: Treat the EU decision as a catalyst watch, not proof of a material earnings upgrade. Reassess after the European Commission decision and disclosures on supply, reimbursement, and launch uptake; favor pullbacks over paying a headline premium. Strong adoption with incremental patients would support the upside case; substitution from existing therapies or constrained access would weaken it.
• TSLA: If the reveal prompts a sharp rally, consider a defined-risk, limited-size fade rather than underwriting the long-dated Roadster as a near-term turnaround. Revisit if Tesla provides verifiable production milestones or evidence of a sustained improvement in deliveries; delays or continued sales weakness would undermine the excitement trade.